Drug name
Last update: Sep 2026GS-1219
Developer(s)
Drug information
Not provided
Not provided
Not provided
Small molecule
INSTI (Integrase strand transfer inhibitor)
https://www.fiercebiotech.com/biotech/gilead-ends-ph-1-trial-after-settling-twice-yearly-treatment-partner-lenacapavir development paused as of July 2026
In phase 1, development paused (last checked 18 Sept. 2026)
not yet approved.
Therapeutic area(s)
- HIV
- Treatment
Administration route
Subcutaneous, Intramuscular, Route of administration is being determined in the clinical program
Associated long-acting platforms
Not provided
Use of drug
- To be determined
- Other/Variable/Unknown : To be determined
Dosage
to be determined
to be determined
to be determined
Development reported as paused by Gilead (https://www.gilead.com/science/pipeline; accessed Sep, 18, 2026)
Not provided
Associated compounds, formulations and regimens
Not provided
Associated technologies
Not provided
Additional information
Developer(s)
Gilead
Drug structure
Scale-up and manufacturing prospects
Not provided
Not provided
Not provided
Not provided
Excipients & delivery device(s)
Not provided
Not provided
Not provided
Not provided
Safety, Efficacy and Evidence Summary
Not provided
Not provided
Not provided
Not provided
There are either no relevant patents or these were not yet submitted to LAPaL